<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01627938</url>
  </required_header>
  <id_info>
    <org_study_id>RUB001CarMS</org_study_id>
    <secondary_id>2010-018508-95</secondary_id>
    <nct_id>NCT01627938</nct_id>
  </id_info>
  <brief_title>Study to Evaluate the Reduction of Cardiac Problems in Multiple Sclerosis Patients With Mitoxantrone and Dexrazoxane in Combination</brief_title>
  <acronym>MSCardioPro</acronym>
  <official_title>A Phase II Proof of Concept Study Evaluating the Reduction of Mitoxantrone-induced Cardiotoxicity and Neurological Outcome in the Combined Use of Mitoxantrone and Dexrazoxane (Cardioxane®) in Multiple Sclerosis (MSCardioPro)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>PD Dr. Andrew Chan</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ruhr University of Bochum</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will primarily address the question whether the combination of Mitoxantrone
      therapy with dexrazoxane can reduce cardiotoxic side effects in the treatment of Multiple
      Sclerosis patients in comparison to Mitoxantrone monotherapy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      It is designed to provide clinical and paraclinical efficacy and safety data for dexrazoxane
      in Mitoxantrone treatment of Multiple Sclerosis in order to investigate the possible positive
      influence of dexrazoxane on cardiac function of Mitoxantrone-affected myocardial tissue and
      on the possible augmented clinical efficacy of Mitoxantrone in combination with dexrazoxane
      on neurological outcome parameters. The incidence of cardiotoxicity during combined
      Mitoxantrone/dexrazoxane treatment will be investigated and compared to the standard
      Mitoxantrone-treatment without dexrazoxane.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>April 2012</start_date>
  <completion_date type="Anticipated">April 2016</completion_date>
  <primary_completion_date type="Anticipated">April 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes in LVEF in the different treatment arms by cardiac MRI</measure>
    <time_frame>Baseline to month 12</time_frame>
    <description>Assessment of cardiac function by measurement of LVEF in mitoxantrone plus dexrazoxane treatment arm versus mitoxantrone plus placebo treatment arm by cardiac MRI</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in LVEF by transthoracic echocardiography and determination of cardiac side effects by ECG and by measurement of CK-MB, Troponin and BNP in mitoxantrone plus dexrazoxane versus mitoxantrone plus placebo treatment arms</measure>
    <time_frame>Baseline and month 3,6,9,12, 24</time_frame>
    <description>Assessment of cardiac function by measurement of LVEF by transthoracic echocardiography, by determination of cardiac side effects by ECG and by measurement of CK-MB, Troponin and BNP in mitoxantrone plus dexrazoxane treatment arm versus mitoxantrone plus placebo treatment arm</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Determination of EDSS and relapse rate in mitoxantrone plus dexrazoxane treatment arm versus mitoxantrone plus placebo treatment arm</measure>
    <time_frame>Baseline and month 3,6,9,12 and 24</time_frame>
    <description>Comparison of clinical efficacy of mitoxantrone plus dexrazoxane treatment versus mitoxantrone plus placebo treatment on neurological outcome parameters by means of EDSS and relapse rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative number of active lesions by cMRI</measure>
    <time_frame>Day1 and month 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>LVEF in 3D-echocardiography vs. LVEF in cardiac MRI</measure>
    <time_frame>Baseline and month 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical efficacy of DRZ+MX vs. MX monotherapy by MSFC</measure>
    <time_frame>Baseline and month 3,6,9,12 and 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life by SF-36 questionnaire</measure>
    <time_frame>Baseline and month 3,6,9 and month 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in magnetic evoked potentials: prolongation of TMCT+CMCT, potential configuration</measure>
    <time_frame>Baseline and month 3,6,9 and month 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Annual brain atrophy rates in cMRI</measure>
    <time_frame>Day 1 and month 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in transcranial sonography (abnormal iron deposition AID). AID in cMRI. Comparison of both methods</measure>
    <time_frame>Baseline and month 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Analysis of ABD transporter gene polymorphisms as predictor of therapy response and side effect profile via TaqMan PCR</measure>
    <time_frame>Baseline and month 12</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Multiple Sclerosis</condition>
  <arm_group>
    <arm_group_label>Dexrazoxane (DRZ) plus Mitoxantrone (MX)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>DRZ (600 mg/m2) : MX (12 mg/m2) ratio 50:1</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo plus Mitoxantrone (MX)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo + MX (12 mg/m2)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexrazoxane (DRZ) plus Mitoxantrone (MX)</intervention_name>
    <description>Dosage: DRZ (600 mg/m2) : MX (12 mg/m2) ratio 50:1 DRZ infusion / MX infusion once every three months over a period of 12 months, i.e. 5 infusions</description>
    <arm_group_label>Dexrazoxane (DRZ) plus Mitoxantrone (MX)</arm_group_label>
    <other_name>Cardioxane® (Dexrazoxane)</other_name>
    <other_name>Ralenova® (Mitoxantrone)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo plus Mitoxantrone (MX)</intervention_name>
    <description>MX Dosage: 12mg/m2 Placebo infusion / MX infusion once every three months over a period of 12 months, i.e. 5 infusions</description>
    <arm_group_label>Placebo plus Mitoxantrone (MX)</arm_group_label>
    <other_name>Ralenova ® (Mitoxantrone)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Written informed consent to participate in the study

          -  Male or female subject is 18 years of age to 55 years of age

          -  Subject must have one of the below mentioned confirmed diagnoses of Multiple
             Sclerosis: RRMS or CPMS according to rev. McDonald Criteria (2005)

          -  If female of childbearing potential: Will to practice reliable birth control measures
             during study treatment and for at least 6 months after completion of study medication;
             not lactating or pregnant; and has a documented negative pregnancy test result within
             72 hours prior to study medication administration. Male study participants: Will to
             practice reliable birth control measures during study treatment and for at least 6
             months after completion of study medication

          -  Subject is willing to participate in the study, follow protocol study treatment
             regimen, and comply with all planned assessments

          -  Mitoxantrone treatment indication is given according to current guidelines:

               -  Relapsing progressive or secondary progressive MS with/without superimposed
                  relapses

               -  EDSS 3-6; EDSS deterioration ≥1 point over last 18 months or 2 relapses

               -  non-response or non-tolerability of pre-treatment

          -  ≥ 48 mg/m² BSA MX dose received up to baseline visit as lifetime dosage before study
             entry. If the patient is under regular ongoing MX treatment, the infusion interval of
             3 months must be obtained (see exclusion criteria)

        Exclusion Criteria:

          -  Concomitant clinically suspected or confirmed neurologic disorder at study entry that
             may interfere with the evaluation in this protocol [i.e. EDSS, MSFC, MEP or MRI
             measurements]

          -  Pre-Treatment with DRZ or immunosuppressive drugs of the anthracycline family with
             cardiotoxic potential other than MX prior to study enrollment

          -  Last Treatment with MX within the past 84 days prior to study enrollment (regular
             3-monthly intervals must be obtained)

          -  History of hypersensitivity to any of the study drugs or to drugs with similar
             chemical structures

          -  Pregnant or nursing (lactating) women, where pregnancy is defined as the state of a
             female after conception and until the termination of gestation, confirmed by a
             positive HCG laboratory test (&gt;5 mIU/ml)

          -  Unwillingness to perform adequate contraception

          -  Use of other investigational drugs at the time of enrollment, or within 30 days or 5
             half-lives of enrollment, whichever is longer

          -  Subjects unable or unwilling to adhere to the study-designated procedures and
             restrictions

          -  Patients not able to perform cardiac/neurological investigations including MRI, e.g.
             hypersensitivity to MRI contrast agent

          -  Other known contraindication for DRZ or MX according to current labelling

          -  Subject has a pre-existing cardiac disease interfering with left ventricular ejection
             fraction, i.e. cardiac insufficience for different reasons (resulting from prior
             cardial conditions such as myocardial infarction, myocarditis)

          -  Routine co-administration of cortisone-pulse therapy (other than for treatment of
             relapses), intrathecal triamcinolone-therapy or other off-label/ investigational
             agents (e.g. fampridine, aminopyridine)

          -  History of malignancy in the past 5 years (excluding localized basal cell carcinoma of
             the skin)

          -  Pre-Treatment with other immunosuppressive drugs (azathioprine, methotrexate,
             mycophenolate, cyclophosphamide) within the past 3 months

          -  Pre-Treatment with monoclonal antibodies (natalizumab, rituximab) within the past 6
             months
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andrew Chan, PD Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Neurology, St. Josef-Hospital Bochum, Ruhr-University Bochum</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Neurology, St. Josef-Hospital, Ruhr-University Bochum</name>
      <address>
        <city>Bochum</city>
        <zip>44791</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <reference>
    <citation>Flachenecker P, Meissner H. Fatigue in multiple sclerosis presenting as acute relapse: subjective and objective assessment. Mult Scler. 2008 Mar;14(2):274-7. doi: 10.1177/1352458507082480.</citation>
    <PMID>18337428</PMID>
  </reference>
  <reference>
    <citation>Morrissey SP, Le Page E, Edan G. Mitoxantrone in the treatment of multiple sclerosis. Int MS J. 2005 Nov;12(3):74-87. Review.</citation>
    <PMID>16417821</PMID>
  </reference>
  <reference>
    <citation>Rieckmann P, Toyka KV, Bassetti C, Beer K, Beer S, Buettner U, Chofflon M, Götschi-Fuchs M, Hess K, Kappos L, Kesselring J, Goebels N, Ludin HP, Mattle H, Schluep M, Vaney C, Baumhackl U, Berger T, Deisenhammer F, Fazekas F, Freimüller M, Kollegger H, Kristoferitsch W, Lassmann H, Markut H, Strasser-Fuchs S, Vass K, Altenkirch H, Bamborschke S, Baum K, Benecke R, Brück W, Dommasch D, Elias WG, Gass A, Gehlen W, Haas J, Haferkamp G, Hanefeld F, Hartung HP, Heesen C, Heidenreich F, Heitmann R, Hemmer B, Hense T, Hohlfeld R, Janzen RW, Japp G, Jung S, Jügelt E, Koehler J, Kölmel W, König N, Lowitzsch K, Manegold U, Melms A, Mertin J, Oschmann P, Petereit HF, Pette M, Pöhlau D, Pohl D, Poser S, Sailer M, Schmidt S, Schock G, Schulz M, Schwarz S, Seidel D, Sommer N, Stangel M, Stark E, Steinbrecher A, Tumani H, Voltz R, Weber F, Weinrich W, Weissert R, Wiendl H, Wiethölter H, Wildemann U, Zettl UK, Zipp F, Zschenderlein R, Izquierdo G, Kirjazovas A, Packauskas L, Miller D, Koncan Vracko B, Millers A, Orologas A, Panellus M, Sindic CJ, Bratic M, Svraka A, Vella NR, Stelmasiak Z, Selmaj K, Bartosik-Psujik H, Mitosek-Szewczyk K, Belniak E, Mochecka A, Bayas A, Chan A, Flachenecker P, Gold R, Kallmann B, Leussink V, Mäurer M, Ruprecht K, Stoll G, Weilbach FX; Multiple Sclerosis Therapy Consensus Group. Escalating immunotherapy of multiple sclerosis--new aspects and practical application. J Neurol. 2004 Nov;251(11):1329-39. Review.</citation>
    <PMID>15592728</PMID>
  </reference>
  <reference>
    <citation>Spindler M, Weilbach F, Beer M, Sandstede J, Köstler H, Strotmann J, Voelker W, Hahn D, Ertl G, Gold R. Non-invasive functional and biochemical assessment of mitoxantrone cardiotoxicity in patients with multiple sclerosis. J Cardiovasc Pharmacol. 2003 Nov;42(5):680-7.</citation>
    <PMID>14576518</PMID>
  </reference>
  <reference>
    <citation>Weilbach FX, Chan A, Toyka KV, Gold R. The cardioprotector dexrazoxane augments therapeutic efficacy of mitoxantrone in experimental autoimmune encephalomyelitis. Clin Exp Immunol. 2004 Jan;135(1):49-55.</citation>
    <PMID>14678264</PMID>
  </reference>
  <reference>
    <citation>Bernitsas E, Wei W, Mikol DD. Suppression of mitoxantrone cardiotoxicity in multiple sclerosis patients by dexrazoxane. Ann Neurol. 2006 Jan;59(1):206-9.</citation>
    <PMID>16374818</PMID>
  </reference>
  <reference>
    <citation>Cotte S, von Ahsen N, Kruse N, Huber B, Winkelmann A, Zettl UK, Starck M, König N, Tellez N, Dörr J, Paul F, Zipp F, Lühder F, Koepsell H, Pannek H, Montalban X, Gold R, Chan A. ABC-transporter gene-polymorphisms are potential pharmacogenetic markers for mitoxantrone response in multiple sclerosis. Brain. 2009 Sep;132(Pt 9):2517-30. doi: 10.1093/brain/awp164. Epub 2009 Jul 15.</citation>
    <PMID>19605531</PMID>
  </reference>
  <reference>
    <citation>Dörr J, Bitsch A, Schmailzl KJ, Chan A, von Ahsen N, Hummel M, Varon R, Lill CM, Vogel HP, Zipp F, Paul F. Severe cardiac failure in a patient with multiple sclerosis following low-dose mitoxantrone treatment. Neurology. 2009 Sep 22;73(12):991-3. doi: 10.1212/WNL.0b013e3181b878f6.</citation>
    <PMID>19770476</PMID>
  </reference>
  <reference>
    <citation>Hartung HP, Gonsette R, König N, Kwiecinski H, Guseo A, Morrissey SP, Krapf H, Zwingers T; Mitoxantrone in Multiple Sclerosis Study Group (MIMS). Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, randomised, multicentre trial. Lancet. 2002 Dec 21-28;360(9350):2018-25.</citation>
    <PMID>12504397</PMID>
  </reference>
  <verification_date>November 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 30, 2012</study_first_submitted>
  <study_first_submitted_qc>June 25, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 26, 2012</study_first_posted>
  <last_update_submitted>November 4, 2014</last_update_submitted>
  <last_update_submitted_qc>November 4, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 5, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Ruhr University of Bochum</investigator_affiliation>
    <investigator_full_name>PD Dr. Andrew Chan</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Multiple Sclerosis</keyword>
  <keyword>MS</keyword>
  <keyword>Mitoxantrone</keyword>
  <keyword>Dexrazoxane</keyword>
  <keyword>Cardioxane</keyword>
  <keyword>cardiotoxicity</keyword>
  <keyword>cardiac toxicity</keyword>
  <keyword>cardiotoxic side effects</keyword>
  <keyword>cardiac MRI</keyword>
  <keyword>cranial MRI</keyword>
  <keyword>LVEF</keyword>
  <keyword>neurological outcome</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sclerosis</mesh_term>
    <mesh_term>Multiple Sclerosis</mesh_term>
    <mesh_term>Cardiotoxicity</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mitoxantrone</mesh_term>
    <mesh_term>Dexrazoxane</mesh_term>
    <mesh_term>Razoxane</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

